The startup has developed a tri-specific drug creation platform that utilizes anti-angiogenesis-based artifact re-targeting (ART) to create multi-target therapeutics for cancer treatment. This approach minimizes the side effects associated with single-target protein therapies while expanding the pipeline for novel cancer drugs.
Funding
$17.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer treatments often rely on single-target protein therapies, which can lead to significant side effects and limited efficacy due to the complex nature of tumor biology and the tumor microenvironment. Developing multi-specific biologics to address these challenges is difficult and can be expensive.
Solution
Panolos Bioscience has developed the αART™ (Anti-angiogenesis-based Artifact Re-targeting Tri-specific) platform, a structure-based technology for creating multi-specific biologics. This platform leverages a fusion protein combining a glycosylated VEGF decoy receptor with an antibody Fc region to inhibit angiogenesis. The αART™ platform normalizes the tumor microenvironment by reducing abnormal blood vessel formation and promoting the infiltration of anti-tumor immune cells. The platform's modular design allows for the addition of functionalities at the N- and C-termini, enabling the creation of therapeutics with tailored specificities and mechanisms of action.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel cancer therapeutics and immunotherapies.
Features
- αART™ platform enables the development of multi-specific biologics from a single plasmid with a single promoter, simplifying manufacturing and reducing costs.
- The VEGFR1(D2D3) domain acts as a long, stable linker, minimizing structural interference between fused active agents.
- The platform's anti-angiogenic activity normalizes tumor microenvironments, reducing CD31+ vascular markers and increasing CD8+ T cell infiltration.
- The platform's PlGF inhibition can be leveraged to develop therapies for autoimmune diseases like rheumatoid arthritis by fusing with scFv of immunosuppressive antibodies.
- Pipeline includes PB101 (in Phase 1 clinical trials), PB203 (preclinical), and PB301 (preclinical) targeting oncology and immuno-oncology indications.